| Literature DB >> 27421971 |
Cecilia Marini1,2,3, Angelina Cistaro4, Cristina Campi5, Andrea Calvo6,7, Claudia Caponnetto8,9, Flavio Mariano Nobili8,9, Piercarlo Fania4, Mauro C Beltrametti10, Cristina Moglia6,7, Giovanni Novi8,9, Ambra Buschiazzo11, Annalisa Perasso5, Antonio Canosa6,7, Carlo Scialò8,9, Elena Pomposelli11, Anna Maria Massone5, Maria Caludia Bagnara12, Stefania Cammarosano6,7, Paolo Bruzzi13, Silvia Morbelli11, Gianmario Sambuceti11, Gianluigi Mancardi8,9, Michele Piana5,10, Adriano Chiò6,7.
Abstract
PURPOSE: In amyotrophic lateral sclerosis, functional alterations within the brain have been intensively assessed, while progression of lower motor neuron damage has scarcely been defined. The aim of the present study was to develop a computational method to systematically evaluate spinal cord metabolism as a tool to monitor disease mechanisms.Entities:
Keywords: Amyotrophic lateral sclerosis; Neuroimaging; PET/CT; Spinal cord
Mesh:
Substances:
Year: 2016 PMID: 27421971 PMCID: PMC5007279 DOI: 10.1007/s00259-016-3440-3
Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN: 1619-7070 Impact factor: 9.236
Fig. 1a Detection of spinal canal and spinal cord at different heights of the vertebral column. The Hough transform-based procedure with respect to the curve with three convexities allows identification of the spinal canal (blue line), while the spinal cord is detected by the Hough transform-based procedure with respect to the ellipse (green line). b Left to right: edge detection of a CT slice in the vertebral region; edge points inside the region bounded by the curve with three convexities; and the curve with three convexities (blue line) and the ellipse (green line) detected by applying the Hough transform-based procedure. c Left to right: fusion of CT and PET data for the slice considered in b zoomed on the spinal region, and histograms of the behaviour of the normalized standardized uptake values for the same slice and along two specific projections highlighted in red
Demographic characteristics of patient populations
| Characteristic | Control subjects | ALS patients |
|---|---|---|
| Age (years) | ||
| Mean ± SD | 60 ± 13 | 66 ± 11 |
| Median (range) | 59 (33 – 79) | 69 (34 – 82) |
| Number of subjects | ||
| Men | 20 | 20 |
| Women | 10 | 10 |
| Ideal body weight (kg), mean ± SD | 66 ± 9 | 66 ± 9 |
| Time from ALS diagnosis to PET/CT (months) | ||
| Mean ± SD | – | 18 ± 15 |
| Median (range) | – | 17 (2 – 69) |
| ALS functional rating scale score | ||
| Mean ± SD | – | 39 ± 5 |
| Median (range) | – | 39 (20 – 46) |
| Riluzole therapy, | – | 21 |
| Serum glucose (mg/dL) | ||
| Mean ± SD | 98 ± 13 | 102 ± 12 |
| Median (range) | 100 (73 – 130) | 98 (69 – 129) |
| Follow-up after PET/CT (months) | ||
| Mean ± SD | 24 | 14 ± 7 |
| Median (range) | – | 16 (1 – 36) |
| Number of deaths during follow-up | 0 | 13 |
Fig. 2a Sagittal whole-body CT scan (left) and the corresponding image showing extraction of the cervical (red) and dorsal (green) spinal canal. b–d Volumes of the spinal canal (solid bars) and spinal cord (hatched bars) in the control subjects (CTR) and in the 30 ALS patients (ALS): b total volumes, c cervical region, d dorsal region. There are no differences between the control subjects and ALS patients. e, f Linear regression analysis of the relationship between spinal canal volume (e) and spinal cord volume (f) and ideal body weight
Fig. 3a, b Whole-body maximum intensity projection CT images coregistered with the extracted PET data for the spinal cord in a control subject (a CTR) and an ALS patient (b ALS). The PET data alone are also shown for the corresponding SCs as the average SUV normalized to the corresponding liver values (average NSUV) together with images of the cervical and dorsal segments. c–e Average NSUV for the spinal canal (solid bars) and spinal cord (hatched bars) in control subjects (CTR) and 30 ALS patients (ALS): c whole spinal cord/spinal canal, d cervical segment, e dorsal segment. FDG uptake in the spinal cord was significantly lower in control subjects for the whole spinal cord (c) and for the cervical segment (d), but not for the dorsal segment (e). *p < 0.05
Fig. 4a, c, e Linear regression analysis of the relationship between spinal cord (SC) NSUV and patient age (a), time between diagnosis and imaging (c) and revised ALS functional rating scale (ALSFR-S) score (e). b, d, f The spinal cord metabolic pattern (in terms of NSUV) was not significantly different between male (M) and female (F) patients (b), or between those treated and those not treated with riluzole (d), but SC NSUV was significantly higher in patients who had died (Nonsurvivors) than in those who were still alive (Survivors) at the end of the 36-month follow-up period (f). *p < 0.05
Fig. 5Kaplan-Meier curves showing overall survival in patients with SC_NSUV above and below the fifth decile. High FDG uptake in the whole spinal cord was associated with a higher mortality rate
Prediction of death
| Variable | Outcome resultsa | Univariate analysis | Multivariate analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of patients | No. of deaths | Mortality rate (%) | Hazard ratio | 95 % confidence interval |
| Hazard ratio | 95 % confidence interval |
| |||
| For heterogeneity | For trend | For heterogeneity | For trend | ||||||||
| Age (three categories) | |||||||||||
| ≤63 years | 10 | 3 | 30 | 1 (reference) | – | 0.213 | 0.810 | 1 (reference) | – | 0.055 | 0.226 |
| 64 – 72 years | 10 | 4 | 40 | 3.20 | 0.74 – 13.84 | 7.45 | 1.20 – 46.37 | ||||
| ≥73 years | 10 | 6 | 60 | 1.22 | 0.24 – 6.09 | 6.56 | 0.45 – 95.11 | ||||
| ALS score (three categories) | |||||||||||
| ≤38 | 10 | 4 | 40 | 1 (reference) | – | 0.323 | 0.280 | 1 (reference) | – | 0.082 | 0.374 |
| 39 – 42 | 10 | 4 | 40 | 1.39 | 0.35 – 5.51 | 2.06 | 0.36 – 11.64 | ||||
| ≥43 | 10 | 5 | 50 | 0.43 | 0.09 – 1.98 | 0.30 | 0.04 – 2.15 | ||||
| Time from diagnosis to PET/CT (three categories) | |||||||||||
| ≤9 months | 9 | 6 | 67 | 1 (reference) | – | 0.367 | 0.240 | –b | – | 0.86 | – |
| 10 – 19 months | 14 | 3 | 21 | 0.41 | 0.10 – 1.74 | – | – | ||||
| ≥20 months | 7 | 4 | 57 | 0.45 | 0.11 – 1.86 | – | – | ||||
| Riluzole treatment | |||||||||||
| No | 9 | 4 | 44 | 1 (reference) | – | 0.488 | – | –b | – | 0.51 | – |
| Yes | 21 | 9 | 43 | 1.54 | 0.45 – 5.27 | – | – | ||||
| Sex | |||||||||||
| Female | 10 | 4 | 40 | 1 (reference) | – | 0.272 | – | 1 (reference) | – | 0.049 | – |
| Male | 20 | 9 | 45 | 2.02 | 0.54 – 7.56 | 4.43 | 0.87 – 22.55 | ||||
| Average normalized spinal cord SUV (>5th decile) | |||||||||||
| ≤0.67 | 16 | 3 | 19 | 1 (reference) | – | 0.003 | – | 1 (reference) | – | 0.01 | – |
| >0.67 | 14 | 10 | 71 | 6.87 | 1.50 – 31.58 | 24.3 | 2.25 – 262.77 | ||||
aTotal 30 patients, 13 died, overall mortality rate 43 %
bRemoved from the final Cox multivariate model (p > 0.1)